A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients

Maha Ayyoub, Naira E. Souleimanian, Emmanuelle Godefroy, Luigi Scotto, Charles S. Hesdorffer, Lloyd J. Old, Danila Valmori

Research output: Contribution to journalArticle

Abstract

Because of its frequent expression in tumors and spontaneous immunogenicity in advanced cancer patients, NY-ESO-1 is presently viewed as a prototype tumor antigen for the development of cancer vaccines. A prerequisite for the analysis of NY-ESO-1-specific T cell responses in vaccinated patients is the assessment of the complete T cell repertoire available for the antigen. Here, we have assessed frequency and fine specificity of CD4+ T cells reactive against NY-ESO-1-derived sequences in circulating lymphocytes from cancer patients with spontaneous responses to the antigen. We found that, relative to healthy donors, this frequency was only moderately increased in cancer patients. The reactivity of these cells, however, was directed against the same immunodominant regions previously identified for healthy donors. On account of these data, we developed an approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses based on the assessment of CD4+ T cell populations of defined phenotype. Using this approach, a similar frequency of NY-ESO-1-specific CD4+ T cells was found among naive T cells of healthy donors and cancer patients. In contrast, among antigen-experienced T cells, NY-ESO-1-specific CD4+ T cells were exclusively detectable in cancer patients. We anticipate that this phenotype-based approach will be useful for the immune monitoring of vaccine-induced responses in vaccination trials using NY-ESO-1 as well as other tumor antigens.

Original languageEnglish (US)
Pages (from-to)188-194
Number of pages7
JournalClinical Immunology
Volume118
Issue number2-3
DOIs
StatePublished - Feb 2006
Externally publishedYes

Fingerprint

Immunologic Monitoring
T-Lymphocytes
Phenotype
Neoplasms
Tissue Donors
Neoplasm Antigens
Antigens
T-Cell Antigen Receptor Specificity
Immunodominant Epitopes
Cancer Vaccines
Vaccination
Vaccines
Lymphocytes

Keywords

  • CD4 T cells
  • Human
  • T cell epitopes
  • Tumor immunity

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Ayyoub, M., Souleimanian, N. E., Godefroy, E., Scotto, L., Hesdorffer, C. S., Old, L. J., & Valmori, D. (2006). A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients. Clinical Immunology, 118(2-3), 188-194. https://doi.org/10.1016/j.clim.2005.10.002

A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients. / Ayyoub, Maha; Souleimanian, Naira E.; Godefroy, Emmanuelle; Scotto, Luigi; Hesdorffer, Charles S.; Old, Lloyd J.; Valmori, Danila.

In: Clinical Immunology, Vol. 118, No. 2-3, 02.2006, p. 188-194.

Research output: Contribution to journalArticle

Ayyoub, M, Souleimanian, NE, Godefroy, E, Scotto, L, Hesdorffer, CS, Old, LJ & Valmori, D 2006, 'A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients', Clinical Immunology, vol. 118, no. 2-3, pp. 188-194. https://doi.org/10.1016/j.clim.2005.10.002
Ayyoub, Maha ; Souleimanian, Naira E. ; Godefroy, Emmanuelle ; Scotto, Luigi ; Hesdorffer, Charles S. ; Old, Lloyd J. ; Valmori, Danila. / A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients. In: Clinical Immunology. 2006 ; Vol. 118, No. 2-3. pp. 188-194.
@article{90cdd9000b4f47769c96f8568a2a4a0b,
title = "A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients",
abstract = "Because of its frequent expression in tumors and spontaneous immunogenicity in advanced cancer patients, NY-ESO-1 is presently viewed as a prototype tumor antigen for the development of cancer vaccines. A prerequisite for the analysis of NY-ESO-1-specific T cell responses in vaccinated patients is the assessment of the complete T cell repertoire available for the antigen. Here, we have assessed frequency and fine specificity of CD4+ T cells reactive against NY-ESO-1-derived sequences in circulating lymphocytes from cancer patients with spontaneous responses to the antigen. We found that, relative to healthy donors, this frequency was only moderately increased in cancer patients. The reactivity of these cells, however, was directed against the same immunodominant regions previously identified for healthy donors. On account of these data, we developed an approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses based on the assessment of CD4+ T cell populations of defined phenotype. Using this approach, a similar frequency of NY-ESO-1-specific CD4+ T cells was found among naive T cells of healthy donors and cancer patients. In contrast, among antigen-experienced T cells, NY-ESO-1-specific CD4+ T cells were exclusively detectable in cancer patients. We anticipate that this phenotype-based approach will be useful for the immune monitoring of vaccine-induced responses in vaccination trials using NY-ESO-1 as well as other tumor antigens.",
keywords = "CD4 T cells, Human, T cell epitopes, Tumor immunity",
author = "Maha Ayyoub and Souleimanian, {Naira E.} and Emmanuelle Godefroy and Luigi Scotto and Hesdorffer, {Charles S.} and Old, {Lloyd J.} and Danila Valmori",
year = "2006",
month = "2",
doi = "10.1016/j.clim.2005.10.002",
language = "English (US)",
volume = "118",
pages = "188--194",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "2-3",

}

TY - JOUR

T1 - A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients

AU - Ayyoub, Maha

AU - Souleimanian, Naira E.

AU - Godefroy, Emmanuelle

AU - Scotto, Luigi

AU - Hesdorffer, Charles S.

AU - Old, Lloyd J.

AU - Valmori, Danila

PY - 2006/2

Y1 - 2006/2

N2 - Because of its frequent expression in tumors and spontaneous immunogenicity in advanced cancer patients, NY-ESO-1 is presently viewed as a prototype tumor antigen for the development of cancer vaccines. A prerequisite for the analysis of NY-ESO-1-specific T cell responses in vaccinated patients is the assessment of the complete T cell repertoire available for the antigen. Here, we have assessed frequency and fine specificity of CD4+ T cells reactive against NY-ESO-1-derived sequences in circulating lymphocytes from cancer patients with spontaneous responses to the antigen. We found that, relative to healthy donors, this frequency was only moderately increased in cancer patients. The reactivity of these cells, however, was directed against the same immunodominant regions previously identified for healthy donors. On account of these data, we developed an approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses based on the assessment of CD4+ T cell populations of defined phenotype. Using this approach, a similar frequency of NY-ESO-1-specific CD4+ T cells was found among naive T cells of healthy donors and cancer patients. In contrast, among antigen-experienced T cells, NY-ESO-1-specific CD4+ T cells were exclusively detectable in cancer patients. We anticipate that this phenotype-based approach will be useful for the immune monitoring of vaccine-induced responses in vaccination trials using NY-ESO-1 as well as other tumor antigens.

AB - Because of its frequent expression in tumors and spontaneous immunogenicity in advanced cancer patients, NY-ESO-1 is presently viewed as a prototype tumor antigen for the development of cancer vaccines. A prerequisite for the analysis of NY-ESO-1-specific T cell responses in vaccinated patients is the assessment of the complete T cell repertoire available for the antigen. Here, we have assessed frequency and fine specificity of CD4+ T cells reactive against NY-ESO-1-derived sequences in circulating lymphocytes from cancer patients with spontaneous responses to the antigen. We found that, relative to healthy donors, this frequency was only moderately increased in cancer patients. The reactivity of these cells, however, was directed against the same immunodominant regions previously identified for healthy donors. On account of these data, we developed an approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses based on the assessment of CD4+ T cell populations of defined phenotype. Using this approach, a similar frequency of NY-ESO-1-specific CD4+ T cells was found among naive T cells of healthy donors and cancer patients. In contrast, among antigen-experienced T cells, NY-ESO-1-specific CD4+ T cells were exclusively detectable in cancer patients. We anticipate that this phenotype-based approach will be useful for the immune monitoring of vaccine-induced responses in vaccination trials using NY-ESO-1 as well as other tumor antigens.

KW - CD4 T cells

KW - Human

KW - T cell epitopes

KW - Tumor immunity

UR - http://www.scopus.com/inward/record.url?scp=32044435651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32044435651&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2005.10.002

DO - 10.1016/j.clim.2005.10.002

M3 - Article

C2 - 16368270

AN - SCOPUS:32044435651

VL - 118

SP - 188

EP - 194

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 2-3

ER -